Clozapine and Pulmonary Embolism Risk
Yes, clozapine is associated with an increased risk of pulmonary embolism (PE), and this risk should be actively monitored and considered when prescribing this medication.
Evidence from Guidelines and FDA Labeling
The most recent 2026 global consensus guidelines from The Lancet Psychiatry explicitly identify pulmonary embolism as a less common but serious adverse event that must be considered in patients taking clozapine 1. The FDA drug label directly warns that "pulmonary embolism and deep-vein thrombosis have occurred in patients treated with clozapine" and instructs clinicians to consider PE in patients presenting with deep-vein thrombosis, acute dyspnea, chest pain, or other respiratory symptoms 2.
However, both the FDA label and current evidence acknowledge uncertainty: "Whether pulmonary embolus and deep-vein thrombosis can be attributed to clozapine or some characteristic(s) of patients is not clear" 2.
Magnitude and Characteristics of the Risk
Research evidence consistently demonstrates this association:
A 2024 pharmacovigilance analysis of the FDA Adverse Event Reporting System found clozapine significantly associated with PE (n=234 cases), with antipsychotics overall showing a doubled risk (ROR 2.00,95% CI 1.91-2.10) 3
A 2019 systematic review of 34 cases found 36.36% mortality from clozapine-associated PE, with nearly half of patients (47.82%) having no other comorbidities for PE besides clozapine use 4
The risk appears highest in the first 6 months of treatment: 71.8% of VTE events occurred within this timeframe in one review 5, and 87% had early onset (6.4 ± 7.0 weeks) in another 6
The risk is dose-independent: PE has occurred at doses as low as 152.8 ± 50.7 mg/day, well below the typical therapeutic range 6
A 2015 population-based study found current antipsychotic use more than doubled PE risk (OR 2.31,95% CI 1.16-4.59), with concomitant use of both conventional and atypical antipsychotics quadrupling the risk 7
Clinical Implications and Monitoring Strategy
Given the high mortality (26-36%), early onset, and dose-independent nature of clozapine-associated PE, vigilant monitoring is essential, particularly in the first 6 months of treatment 6.
Risk Assessment Before Initiating Clozapine:
- Identify pre-existing VTE risk factors (87.5% of cases had such factors) 5
- Document comorbidities (70.37% had comorbidities at VTE onset) 5
- Review concomitant medications, especially other antipsychotics (60% were on another antipsychotic at VTE onset) 5
Active Monitoring During Treatment:
- Educate patients to immediately report: acute dyspnea, chest pain, leg swelling, or respiratory symptoms 2
- Maintain heightened vigilance during the first 6 months, when risk is highest 5, 6
- Consider lower extremity examination for signs of deep vein thrombosis at regular intervals
Management When PE Occurs:
- Anticoagulation is the primary treatment (used in 80% of reported cases) 4
- Clozapine discontinuation occurred in 60-78% of cases 5, 4, though recent case reports demonstrate successful continuation with concurrent anticoagulation in selected patients 8
- The decision to continue or discontinue clozapine must weigh the severity of psychiatric illness against thrombotic risk
Important Caveats
The absolute risk remains uncertain because most evidence comes from case reports and pharmacovigilance databases rather than prospective controlled trials. The 2026 guidelines list PE among adverse events to "consider" but do not mandate specific screening protocols 1.
No consensus exists on prophylactic anticoagulation, though one systematic review suggested consideration of prophylactic treatment for 6 months after starting clozapine given the early-onset, dose-independent, and highly lethal nature of this complication 6. However, this remains an area requiring further research 8.
The risk may be partially attributable to patient characteristics rather than clozapine itself, including immobility, obesity, and metabolic syndrome—all common in patients with schizophrenia 4. The FDA label acknowledges this uncertainty 2.